{"title": "PDF", "author": "PDF", "url": "https://eziz.org/assets/docs/COVID19/10.14.22ProviderWebinar.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "Friday, October 14, 2022 9:00AM -10:30AMWelcome to the COVID -19 and Monkeypox (MPX) Weekly Provider Webinar 1 Questions 2 During today's session, please use the Q&A panel to ask your questions so CDPH subject matter experts can respond directly . Resource links will be dropped into, \"Chat\" Housekeeping Reminder to Panelists: Please mute yourself when not speaking. Please monitor the Q&A panel for questions you may be able to answer. Reminder to Attendees : Today's session is being recorded. Access today's slides and archived presentations at: https://eziz.org/covid/education/ If you have post -webinar questions, please email leslie.amani@cdph.ca.gov 3 4Agenda: Friday, October 14, 2022 No. Item Speaker Time (AM) 1 Welcome Leslie Amani (Moderator) 9:00 -9:02 2 Long -term , Clinical Caterina Liu, and Handling Hendrickson (CDPH) 9:15 -9:20 6 Vaccine Management Josh Pocus (My Turn) and Maria Volk (CDPH) 9:20 -9:25 7 Amani, CDPH 5Upcoming Crucial Conversations Webinar: Talking with Patients about Long COVID Please join Atul Nakhasi , M.D., co -founder of #ThisIsOurShot and Senior Advisor to the U.S. Surgeon General, to discuss talking with patients about long COVID. When: Thursday, October 27 at 12:00PM Register here! 6 Photo credit: Washington Post articleCOVID (POM) 7Please bookmark this comprehensive resource! CDPH will begin to retire job aids that are now contained within the COVID -19POM. No more searching across EZIZ for key programmatic and clinical job aids! One-stop shop for all things COVID -19! Quick link to the POM Start -up Guide COVID -19 Provider Operations Manual (POM)Q: Where can new COVID -19 vaccine Provider staff find a startup guide with all key requirements, setup considerations, and documentation of all key tasks? A: New COVID -19 vaccine Provider staff can access a startup guide at California COVID -19 Vaccination Program Provider Operations Manual and a startup worksheet. Moderna Vaccine, Bivalent 6Y+ Fact Sheet Vaccine, Bivalent 6Y+ Fact Sheet |Other Fact SheetsProduct fact sheet also includes this guidance: Authorization Ordering Ancillary Kits Dosing volume Wastage reporting Moderna DHCP Letter Bivalent New Preparation & Administration Summary (one for all products) New Storage/BUD Tracking Labels (one for all products) Pfizer -BioNTech Vaccine, Bivalent 5Y -11Y Fact Sheet 9Pfizer -BioNTech Vaccine, Bivalent 5 -11Y Fact Sheet | Other Fact Sheets Product fact sheet includes: Authorization Shipments Storage and handling Administration NEW! CDC released updated resources; now one for all products: Preparation & Administration Summary Storage/Handling Summary Storage/BUD tracking labels Soon to be updated for bivalent additionsLong -19 Toolkit Long -term Care Facility COVID -19 Vaccine Toolkit 11 LTCF Toolkit includes: Community resources for appointments Listing of retail pharmacies On-site vaccine clinic information Becoming a COVID -19 Vaccine Provider State resources Staff and resident education resources How to access COVID -19 vaccine Listing of LTC pharmacies by county And more... How does your facility get COVID -19 Vaccine? LTCF COVID -19 Vaccine Toolkit12Resources for Long -term Care Facilities Resources for Long -Term Care Facilities Vaccine Guidance COVID -19 Influenza Vaccine Education Promotional Materials COVID -19 Influenza Policy Guidance EZIZ COVID -19 and Flu Resources for Long -term Care Facilities 13Vaccine Administration Data Elizabeth Reosti , CDPH 142,219,309 Total Bivalent Booster Doses Administered:Vaccine Administration Summary as of October 11, 2022 15 Public Dashboard Trends in Vaccine Administration as of October 11, 2022 16Bivalent booster for 12+ Primary series among under 5 First boosters among 5 -11-year-oldsMost Recent Eligibility Groups Distribution of Bivalent Boosters as of October 11, 2022 17Higher uptake among under 65+ population Statewide 7.8% of the eligible population has received a bivalent BoosterInfant/Toddler Vaccination Trends as of October 11, 2022 18Modest uptake in Under 5 Higher uptake in Healthier Places (Q3-Q4)Key Metrics 82.1 million doses administered | +2.2 million bivalent booster doses 10.2 %population Under 5 with 1+ dose |+5K new Infant/Toddler recipients 71% population 50+ years with 1+ booster |62-80% range by race and ethnicity System Notes Plans to add bivalent -specific data to public facing or LHJ dashboards Preparing for bivalent booster data for 5 -11-year-oldsData Summary Data Summary as of October 11, 2022 19Clinical Update Caterina Liu, M.D., CDPH 20Updated Boosters Now Authorized and Recommended for Children 10/12/22: FDA issued Emergency Use Authorization (EUA) for updated (bivalent) booster for pediatric populations: Pfizer FDA fact sheet forHCP :5-11 years -0.2ml dose Moderna FDA fact 6-11 years -0.25 ml dose; 12+ years -0.5 ml dose CDC has updated their COVID -19 vaccine guidelines to include pediatric updated booster recommendations Western States Scientific Safety Review Workgroup (WSSSRW) released a statement aligning with CDC's updated booster guidelines. 21FDA Authorizes Bivalent Booster Dose in Younger Ages CDC Updates COVID -19 Vaccines Include Children Ages 5 -11 | CDC Online Newsroom | CDC Western States Scientific Safety Review Workgroup Statement on Bivalent COVID -19 Boosters for ChildrenUpdated Boosters People ages 5 years and older are recommended to receive 1 age -appropriate bivalent mRNA booster dose after completion of any FDA -approved or FDA -authorized monovalent primary series or previously received monovalent booster dose(s). Can be administered at least 2 months after either completion of the primary series or last monovalent booster dose. This new booster recommendation replaces all prior booster recommendations for this age group. Monovalent mRNA vaccines are no longer authorized as a booster dose for people ages 5 years and older. Only monovalent vaccines are approved or authorized for primary series doses. J&J vaccine remains available as first booster for certain people 22Interim Clinical Considerations for Use of COVID -19 Vaccines Currently Approved or Authorized in the United StatesPediatric Bivalent Booster Dosage Bivalent booster dose is same as prior monovalent booster dose. 23 CDC COVID -19 Vaccine Clinical Considerations Guidance ACIP Meeting Next Week CDC Advisory Committee on Immunization Practices (ACIP) is scheduled to meet October 19-20, 2022. COVID -19 Vaccine Agenda topics: COVID -19 in pregnant people COVID -19 in infants ages <6 months and effectiveness of maternal COVID -19 vaccination in pregnant people and infants COVID -19 vaccine safety in pregnant people COVID -19 vaccines in children Vaccines for Children 24ACIP Meeting Agenda October 19 -20 2022 (cdc.gov )ACIP Meetings Information | CDCCOVID -19 and Flu Vaccine Coadministration Routine administration of all age -appropriate doses of vaccines simultaneously is recommended for persons for whom no specific contraindications exist. COVID -19 vaccines may be administered regardless of timing of influenza vaccines, including simultaneous administration of COVID -19 and influenza vaccines on the same day. Administer each vaccine in a different injection site (at least 1 inch apart) Administer vaccines that may be more likely to cause a local reaction (e.g., tetanus - toxoid -containing and PCV13, adjuvanted or high -dose influenza) in different limbs, if possible. 25CDC Adminstration of and COVID -19 Vaccines -10-22 (eziz.org) Clinical Guidance for COVID -19 Vaccination | CDC Vaccine Administration Route and Site | CDCNEW! Pediatric COVID -19 Checklist Features simple and effective strategies from high- performing VFC clinics that you can readily implement in your clinic. Includes links to other helpful resources, including: Share it with your clinical team and set a few minutes aside to discuss what strategies you will implement today! Pediatric COVID -19 Checklist 26Storage Pfizer -11Y) Packaging : 10 10 -dose multidose vials per carton and a minimum order of 100 doses. Diluent required. Cap Color : Orange Ships : ULT/dry ice ( -90\u00b0C to -60\u00b0C) Storage : Minimize exposure to light Storage : Expiry (12 months) at ULT (-90\u00b0C to -60\u00b0C) BUD refrigerated : (2\u00b0C to 8 \u00b0C): 10 weeks Storage (continued) : Do not store frozen (-25\u00b0C to -15\u00b0C) BUD room temperature (8 \u00b0C to 25 \u00b0C): 12 hours Do not refreeze Redistribution : ULT (-90\u00b0C to -60\u00b0C) Refrigerated (2\u00b0C to 8 \u00b0C) Thaw Time : 30 minutes to 2 hours Ancillary Supplies : No opt out -diluent 29 COVID -19 Vaccine Product GuidePfizer -BioNTech COVID -19 Orange Cap Labels 30 Moderna Pediatric Bivalent Boosters (6 Years +) Packaging : Ten 5/(10) -dose vials per cartoon, 2 cartons per order, 100 dose minimum order Cap Color : Blue Ships : Frozen ( -50\u00b0C to -15\u00b0C) Storage : Minimize exposure to light Storage : Expiry (8 -9 months) at Frozen (-50\u00b0C to -15\u00b0C) BUD refrigerated : (2\u00b0C to 8 \u00b0C): 30 daysStorage (continued) : BUD Room Temperature : 12 hours after puncture < 24 hours total time Do not refreeze Redistribution : Frozen (-50\u00b0C to -15\u00b0C) Refrigerated (2\u00b0C to 8 \u00b0C) <12 hours travel time Puncture Limit : 20 times 31Moderna Pediatric Bivalent Booster (6 Years +) One Moderna Bivalent Booster (ages 6 plus) : One NDC*, one presentation, one set of storage and handling instructions. The Difference -the dosages : Ages 6 to 11 years: 0.25 mL (up to 10 doses/vial) Ages 12 years plus: 0.5 mL Two ancillary supply kits, pediatric and adult Inventory Reporting : Inventory in adult doses. Any combination of doses = 5 is good. Report wastage as adult doses 32*National Drug CodeModerna Bivalent Booster (6 Years +) 33 AmerisourceBergen AmerisourceBergen redistributes: Pfizer infant/toddler (6 months -4 years), maroon cap Pfizer pediatric (5 years -11 years), orange cap Pfizer adolescent/adult (12+ years), gray cap Pfizer bivalent booster (12+) gray Novavax adolescent/adult (12+ years), blue cap AmerisourceBergen will redistribute: Pfizer bivalent (5 years to 11 years), orange cap (October 24, 2022) 34Shelf Lives, et alia Pfizer Gray Cap Monovalent (12+) : The bulk of the lot #s expire 31 December with small lots into 31 January. Pfizer Orange Cap Monovalent (5 yrs -11yrs) : oCurrently seeing November 30, 2022 oThe promise, April 30, 2023, lot #s just around the corner The Advice : Order small, order often to get the longest shelf life Janssen : Sunsets by February 28, 2023 35Vaccine Management Josh Pocus, My Turn, and Maria Volk, CDPH 365Y-11Y Bivalent Pediatric Update & My Turn Release 32 Delayed 37 Prioritization of R31.4, which went live on Wednesday, October 12 , to support My Turn Clinic and Public functionality for 5Y -11Y Pfizer Pediatric Bivalent Boosters. R32 has been delayed by a week and is now scheduled for Wednesday, October 26, 2022 . 38 Due to planned maintenance, myCAvax andMy Turn Clinic will be unavailable on Saturday, October 15, 2022 ,between 9AM -9:15AM PT . The following error message will appear during this time: 'This instance will not be available during this maintenance window'. My Turn Public will still be live during this time . Planned Maintenance for myCAvax and My Turn Clinic View the New MPX Requirements at a Glance Job Aid 39 The new MPX Requirements at a Glance job aid (accessible via EZIZ ) summarizes the MPX program requirements and operational guidance for LHJs and Providers. It also identifies any differences from the COVID -19 Vaccination Program. Topics include: Clinical & Operational Requirements Vaccine Management Vaccine Administration Billing & Reimbursement Suspension, Termination, Fraud, and Abuse Pfizer Pediatric Bivalent Booster Update 40 We expect initial pre -orders of the Pfizer Pediatric Bivalent vaccine to begin arriving next week . Ancillary supplies may arrive prior to the vaccine. Moderna Pediatric Bivalent Booster Update 41 Changed: Ageindication Issues -Updated 10/10 43 Known Issues Some LHD Users are having issues with approving orders in 'In Review' status We will correct an issue in which LHD users are unable to approve some orders in 'In Review' status. Please be patient as this may cause a slight delay in the ordering approval process. Workaround/Next Steps Estimated Fix: 10/10/2022 44Orders Monkeypox (MPX) Integration with Office of Emergency Services Allow MPX Product during Bulk Allocation New Shipment Record Type for MPX orders Account Remove Status from Account Chatter Feed tracking Allow LHD / MCEs to create / edit Storage Units Allow LHD / MCEs to create Waste Events Site Visits Follow -Up Actions Community Create Waste Events for MPXCommunity Allow for the products look -up in Transfers to be scrollable Do not allow decimals in Waste Events Orders Create an External Order Date field on Vaccine Orders to track when Integration sent the order to the Office of Emergency Services Order Review Breakup Vaccine Order Review page by COVID -19 and Outbreak Transfers Make Transfers available internally Remove non -applicable statuses from Transfer / Redistribution records Training Update training links on the Community pages Storage Units Create a Task when a Storage Capacity record is edited by LHDsOrders Storage Unit logic check to look at Transport Options Add step guide and update Help Desk links on the Multiline Ordering page Product Remove Storage Requirements from Product page layout Order Review Add 'Vaccine Group' to the Vaccine Order Review page filters Automate the Status Update for In -Review Orders Enhance error messages Standardize Product Buckets Remove extra scrollbarRECENTLY DEPLOYED Aug 19th(R29.2.0) and Sep 15th(R30.0)UPCOMING November 3rd(R32.0)IN PROGRESS October 6th(R31.0)myCAvax Release RoadmapMy Turn Public Product Roadmap RECENTLY DEPLOYED September 28th (R31)CURRENT October 12th (R31.4)UPCOMING October 26th(R32)My Turn PublicRelease 31 Novavax for 12 -17 years Bring Flu back on the Public Portal Monkeypox (MPX) Updates Add a screening question to ask if they have been diagnosed with MPX Add a screening question to ask if they received a COVID -19 vaccine within the last 4 weeksRelease 32 SMS and Email Opt -In Remove MPX Date Of Birth validation so patients younger than 6 months can get the vaccine Add new COVID -19 final steps question on whether the patient has received the MPX vaccine Add a note for Third -Party Clinics to check with the clinic about vaccine supplies Refresh Translations Complete Monovalent Boosters disablingRelease 31.4 Pediatric Bivalent Booster rollout Pfizer 5 -11 years Moderna 6 -17 years 45My Turn Clinic Product Roadmap RECENTLY DEPLOYED September 28th (R31)CURRENT October 12th (R31.4)UPCOMING October 26th(R32)My Turn Clinic Received via user feedbackRelease 31 Novavax 12 -17 years Dashboards Clinic Creation Setup Walk -In Flow Update Vaccine Administrator Flow Update Single / Bulk Edit Update Appointment / IIS Tab Filter Update CSV / Inline Bulk Upload Monkeypox (MPX) Updates Add a screening question to ask ifthey have been diagnosed with MPX Add a screening question to askifthey received a COVID -19vaccine within the last 4 weeks Update the risk group question answer options [Single Update] -Appointments 5 -11 years & Moderna 6-17 years Clinic Creation Setup Walk -In Flow Update Vaccine Administrator Flow Update Single / Bulk Edit Update Appointment / IIS Tab Filter Update CSV / Inline Bulk Upload Vaccine Inventory & Vaccine Supply [Walk -In]-Removal of 5 -11 years Monovalent BoosterRelease 32 [Walk Flow] -Make the second Homelessness question optional Add validation to not backdate the past year on: Vaccine Administrator Flow Bulk Upload IIS Tab Filters Relabel Vaccinia to \"Vaccinia (monkeypox)\" Walk -In Flow Clinic Creation Setup Appointment / IIS Tab Filters [Inline Bulk Upload] -Only display active clinics in the picklist Remove warning language on the Booster flow if a patient received Novavax as their Primary Series: Walk -In Flow Vaccine Administrator Flow Add New Appointment button Dashboard Updates Add MPX Add Bivalent Booster Add new values on the MPX Injection Site: Vaccine Administrator Flow IIS Tab Filters CSV / Inline Bulk Upload 46Resources Leslie Amani, CDPH 47Don't Wait -Vaccinate! Campaign Integrate IZ catch up talking points (updated!) into your activities. Tailor and share social media messages/images . Share these resources with providers and schools: Template provider letter to patients (English and Spanish) School letter templates (English and Spanish) 48 #DontWaitVaccinate Archived Communications COVID -19 Therapeutics Listserv To be added, email Kenna.Lee@cdph.ca.gov 49 Don't Wait -Vaccinate! Flu Campaign Integrate 2022 -23 Flu Season Talking Points into your activities Tailor and share social media messages/images Share flu resources with providers and schools 50 Additional Flu Season Resources Fight the Flu Toolkit (CDPH) - Promote flu shots through My Turn ! Flu Communication Resource Center (CDC) Flu and Respiratory Disease Prevention Materials (EZIZ) 51 52Frequent Content Updates:Stay informed! Provider Resources on eziz.org/covid Alerts Program Enrollment My Turn Onboarding Reporting Requirements Patient Resources Archived Communications Education & Support Materials More to explore!COVID -19 Vaccine Provider FAQs 53Answers to provider questions Updated lastupdated 10/13/2022 Currently in its 93rd iteration! Provider FAQs on EZIZ Additional Support Type of Support Description COVID -19 Provider Call CenterThe COVID -19 Call Center for Providers and Local Health Departments is dedicated to medical providers in California and their COVID -19 response, specifically addressing questions about State program requirements, enrollment, and vaccine distribution , including the Vaccine Marketplace. Email: covidcallcenter@cdph.ca.gov Phone: (833) 502 -1245, Monday through -6PM My Turn Clinic Help DeskFor onboarding support (those in the process of onboarding): myturnonboarding@cdph.ca.gov Fortechnical support with My Turn Clinic for COVID -19 and flu vaccines :MyTurn.Clinic.HD@Accenture.com or (833) 502 -1245, option 4: Monday through Friday 8AM -6PM For job aids, demos, and training opportunities : flu at https://eziz.org/covid/myturn/flu/ and COVID at https://eziz.org/covid/myturn/ Dedicated staff provide up-to-date information and technical support myCAvax system. Email: myCAvax.HD@Accenture.com Phone: -6PM For training opportunities: https://eziz.org/covid/education/myCAvax Help Desk For Provider enrollment support, please contact myCAvax Clinic Operations at Email: myCAvaxinfo@cdph.ca.govUpdated 6 .6.22 Archived CommunicationsFor archived communications from the COVID -19 Provider Call Center about the California COVID -19 Vaccination Program visit Website: EZIZ Archived Communications Enrollment Support 54Hear it? Clear It. Trust and Safety Team Our shared mission is to reduce COVID -19 vaccine hesitancy and increase vaccination across the State of California. CTAContactHow You Can Help You are critical in our effort to provide Californians accurate and timely information around COVID -19 vaccination.Monitor What You See and Hear Monitor online media and what you hear in your local communities for potential rumors and inaccurate information. If found, report it torumors@cdph.ca.gov If you see or hear of any vaccine -related rumors within the communities you serve, share them with our Trust and Safety team via the CDPH Rumors Inbox. 55*Pfizer topics vary by day and include the latest information about use of each vaccine presentation, including storage, hand ling, preparation, and administration; recent medical updates and FDA authorizations, healthcare provider resources, and a Q&A session. Note: October platform will be WebEx. View On DemandIntro to My Turn Onboarding (v. 1/4/22) Latest Features in My Turn (Requires My Turn Login)Latest Features in myCAvax for Providers (Requires myCAvax Login) myCAvax Notes for myCAvax Login)CDPH Weekly Provider Webinars Recordings and Slides COVID Crucial Conversations Archived Webinars and Slides HelpCDPH Provider Webinars Webinars and TrainingMy Turn and myCAvax Office Hours 12:00 pm -1:00 pm Pfizer BioNTech COVID -19 Vaccine Training & Education* 12:00 pm -1:00 pmPfizer BioNTech COVID -19 Vaccine Training Education* 9:00 am -10:00 am Pfizer BioNTech COVID -19 Vaccine -10:30 amWeek of October 17, 2022 Calendar Subject to Change Last Updated: 10/14/2256Pfizer COVID -19 Vaccine Updates & Trainings 57Date & Time (linked) Friday, October 14 -12PM Tuesday, October 18 -12PM Wednesday, October 19 -9AM Thursday, October 20 -9AM Tuesday, October 25 -12PM More sessions listed! NOTE: All times listed here are PDT.October 2022 sessions will be held on Webex! Audience: Providers and immunization staff Session Topics Include: Potential authorization of the Pfizer -BioNTech COVID -19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) as a single booster dose for individuals 5 through 11 years of age Note: The Pfizer -BioNTech COVID -19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) has NOT been authorized for use in individuals 5 through 11 years of age in the United States. This topic area is for informational purposes only and is being conducted at the request of the US Government. Use of currently authorized vaccines, including storage, handling, preparation, and administration Question and answer session Pfizer COVID -19 Medical Updates and TrainingsModerna Infant/Toddler Vaccine Video Trainings 58 How to Withdraw a 0.25mL dose: Infant/Toddler 6 months -5 years How to Withdraw a 0.5mL Dose for Pediatrics 6 Years -11YearsQuestions 59 During today's session, please use the Q&A panel to ask your questions so CDPH subject matter experts can respond directly . Resource links will be dropped into, \"Chat\" 60 No.Item Speaker Time (AM) 1 Welcome Leslie Amani (CDPH) 9:30 -9:33 2 Communications Monice Tamara Resources What, When, Where, How? (For Patients) Who: People 12 years or older at higher risk for severe illness are eligible What: Safe and effective medication you can take at home When: Must start within 5 days of getting symptoms. Start treatment early, while symptoms are still mild. Don't delay! Where/How: 1.Get tested (at -home test okay), then 2. a) Ask your health care provider, OR b)Find a Test toTreat location COVID -19 Treatments Toolkit Tip: Call the CDC call line at 1-800-232-0233 for help with finding nearest Test -to-Treat location.63Paxlovid: Patient Questions & Answers How effective is Paxlovid? Paxlovid is up to 88% effective at preventing hospitalization and death. People who take Paxlovid are up to 8x less likely to be hospitalized and up to 10x less likely to die. How does Paxlovid work? Paxlovid is an antiviral medication, so it prevents the virus from multiplying and infecting more of your cells. It prevents your illness from becoming severe. Start taking within 5 days of getting my positive test back or 5 days of starting symptoms?Start treatment within 5 days of starting symptoms! Act fast if you have symptoms. Can both vaccinated and unvaccinated people take treatment?Yes! How much does it cost? FREE! Patients should not be charged for treatment. If you hear of patients being charged, let us know atgo.cdph.ca.gov/ covidpharmacyreportingCOVID rebound is not specific to Paxlovid , occurs in people who have not taken Paxlovid too Paxlovid is very effective at preventing hospitalization and death from COVID -19!People who take Paxlovid are up to 8x less likely to be hospitalized and up to 10x less likely to die. Rebound occurs in less than 1 in 10 people who take Paxlovid. Rebound symptoms are mild. Another Common Question: What is Paxlovid Rebound? 6465 Majority of Adults are Eligible! 50 years or older Obesity Physical inactivity Smoking Moderate/severe asthma Diabetes Hypertension COPD, asthma Unvaccinated And many more conditions! Full list: People with Certain Medical Conditions | CDC Clinical Update Sona Aggarwal, M.D., M.P.H., CDPH hospitalizations 3,690 -7,635 deaths New York Times: The Power of PaxlovidHeadlines Your Patients are Reading 68 Molnupiravir : In the News 69Merck AnnouncementPreliminary analyses released University of Oxford's open label, prospective real -world evidence study, PANORAMIC, UK, >905 vaccination rate, mostly <65 years of age: oNo evidence of a reduction in hospitalizations and deaths through Day 28 (mostly <65) oIncidence of hospitalizations and death through Day 28 very low overall (0.8%) oTime to first self -reported recovery was 6 days shorter Large, real -world Israeli study, Clalit Group: oReduced hospitalizations and mortality in patients 65 years and above oNo evidence of benefit in ages 40 to 64 yearsUpdate: National Institute of Health (NIH) Guideline September 30, 2022: Influenza and COVID -19 Greater disease severity in patients with influenza virus and SARS - CoV-2 coinfection No clinically significant drug -drug interactions between the antiviral agents used to treat influenza and the antiviral agents or immunomodulators used to prevent or treat COVID -19 Community -acquired secondary bacterial pneumonia occurs infrequently in people with COVID -19; it is more common in people with influenza 70Variants & Drug Activity Summary BA.5 -Primary circulating variant and BA.5 Evusheld retains activity against BA.5 but loses activity against BA.4.6 and likely also against BF.7 Continue to follow variants and activity data Bebtelovimab Fact Sheet for Healthcare Providers EvuSheld Fact Sheet for Healthcare Providers Gilead Statement on Veklury (remdesivir) efficacy against variants New England Journal of Medicine Efficacy Article 7172 CDC COVID19 Tracker National COVID -19 VariantsCalifornia Variants from NowCast 73 California COVID Modeling Regional Variant Proportions The connected points in the plot below show actual variant proportions derived from the IGED, while lines in the shaded region/to the right of the vertical line show model -derived projections of variant proportions for the last three weeks. Particularly in regions with small er populations, uncertainty in the actual proportions and projections should be heeded.Therapeutics Are Very Effective 74Drug Class Route Relative Risk Reduction for Severe Disease ( unvax /vax) First Line Paxlovid Antiviral Oral 88%/45% Antiviral Oral Bebtelovimab Monoclonal antibodyIV Decreased symptom duration and viral load; non - inferior to Paxlovid Therapeutics are authorized for patients over 50 or at risk of progression to severe illness (increasing latitude for clinical assessment of risk)Compare to other known relative risk reductions with treatment: Statins to prevent of Therapeutics NIH: National Library of Medicine Glycemic Control Article Recommendations for Population Health Management Pre-screen and prepare patients now who would be at higher risk for severe COVID if infected oAssess and address vaccination status oConsider Evusheld if indicated oPrepare for treatment Identify & note drug interactions, renal function, hepatic function Consider alternative treatments e.g., Remdesivir, Molnupiravir , Bebtelovimab Know and inform patients about treatment timelines and access pathways through your practice or in the community 75Pharmacy Update Edward Salaguinto , Pharm.D., RPh 76Policy Update and Billing Guidance for Paxlovid Emergency Use Authorization (EUA) for Paxlovid allows pharmacists to prescribe Paxlovid under specific circumstances California Board of Pharmacy Order Waiving Restrictions on Pharmacists Independently Initiating and Furnishing Paxlovid to Individual Patients DHCS will reimburse pharmacists for prescribing and/or dispensing Paxlovid when in accordance with California Board of Pharmacy Waiver and the FDA's EUA Medi -Cal NewsFlash : Policy Update and Billing Guidance for Paxlovid 77Important Billing Instructions Department of Healthcare Services (DHCS) will reimburse pharmacists for prescribing (consultation and assessment) Providers will be reimbursed professional dispensing fee only, not the ingredient cost oClaims for reimbursement of the dispensing fee must be submitted to Medi -Cal Rx for processing Claims for consultation and assessment must be billed to DHCS as a Pharmacist Service oReimbursement claims for consultation & assessment (CPT codes 99202 & 99212 ) must be submitted on a CMS 1500 medical claim form oEligible claims must have an ICD -10-CM diagnosis code, U07.1 (COVID -19). oEffective through the end of the declared public health emergency Medi -Cal NewsFlash: Policy Update and Billing Guidance for Paxlovid78Resources Methodology for pharmacist services in Medi -Cal provider manual Providers with questions should contact Medi -Cal Rx at 1-800-977-2273 For more information on services covered by Medi -Cal Rx, providers should refer to the Medi -Cal Rx website. Office Hours :Live assistance via Zoom offered daily from 12 -1pm PT and available upon request Medi -Cal Rx Home Page Medi -Cal Billing Instructions for PharmacistsMedi , CDPH 80Test to Treat Grant Update Test 2 Treat (T2T) Equity Grants: In final review, release grantee award announcements mid -October 81 Health Partner Ordering Portal (HPoP) Tamara Corpin (CDPH) 82HHS: Bebtelovimab CDPH 84Evusheld Expiry AmerisourceBergen is currently redistributing Evusheld with an expiry of December 31, 2022. Plan your Evusheld orders accordingly. The next lot numbers coming available for distribution expire February 28, 2023 Those will not be shipped until the current stockpile is exhausted or nears expiry. 85Molnupiravir Shelf -life Extension FDA grants a shelf -life extension for Molnupiravir capsules from 24 months to 30 months. FDA/ASPR w ebpage updates reflecting the extension are pending We expect the information to become available next week FDA: Molnupiravir Extension Update 86Legacy mAb Tracking to HPoP ) onNovember 2nd. What's Tele-Tracking you ask? Bring zombie mAbs back to life. Need an HPoP account? Please let us know, cdphtherapeutics@cdph.ca.gov . 87Resources Leslie Amani, CDPH 88Resource Summary COVID -19 Preventative Agents and Treatments Therapeutic Management of Nonhospitalized Adults With COVID high flow oxygen/ non-invasive health status, no infectionNothospitalized Nothospitalized None currently authorized for use in any US state or territory.There is currently ample supply of all authorized therapeutics -every eligible patient should have access to these medications Monoclonal Antibodies Bebtelovimab (Lilly) - Alternative 89COVID -19 Therapeutics: Resources and Support Type of Support Description COVID -19 Therapeutics Best Practices Checklist (testing, prescribing, dispensing, and more) Test-to-Treat Playbook (clinical guidance and tools, distribution and logistics, data applications and availability, and best practices) to be updated soonClinical Guidance CDPH COVID -19 Treatments Webpage (provides general information for healthcare providers, allocations, distribution and ordering, drug facts sheets, and additional resources) o CDPH COVID -19 Treatments Job Aid (questions and answers for the public on COVID -19 therapeutics)Updated 9.27.22 QuestionsFor general CDPH Therapeutics questions, please email For ordering, program inquiries, signing up new HPoP Accounts: please e -mail CDPHTherapeutics@cdph.ca.govLocating resources General information Finding Providers and Test -to-Treat Sites COVID -19Therapeutics Locator (arcgis.com) 888 -720-7489) (hhs.gov) 90MPX Update for Providers Friday October 14, 2022 10:00 AM -10:30 AM 91Questions 92 During today's session, please use the Q&A panel to ask your questions so CDPH subject matter experts can respond directly . Resource links will be dropped into \"Chat\" 92Monkeypox (MPX) Provider Webinar Agenda No. Item Speaker Time (AM) 1 Welcome Leslie Amani (Moderator) 10:00 -10:05 2 MPX Reporting Linda Lewis, M.D., CDPH 10:05 -10:10 3 MPX Clinical Update Jessica Watson, M.D., CDPH 10:10 -10:15 4 MPX Vaccine Update Tarek Salih, M.D., CDPH 10:15 -10:25 5 Resources and Q&A Leslie Amani and CDPH MPX Subject Matter Experts 14111968245325873645365540437209820726576 KingdomFranceSpainBrazilUnited States Confirmed cases among countries with highest number of cases reportedConfirmed Cases as of 10/7/22 * global and USA case count from CDC; **deaths reported by WHO : WHO Health Emergency DashboardGlobally: 71,096 confirmed cases as of 10/7/22 cases as last report (10/03) 213Hospitalizations +6reported since last report (10/03) Hospitalized cases account for 5.2% of all cases with a known hospitalization status Source data last updated 2022 -10-11 12:50:4296California R -effective Method: negative binomial spline fit Based on California data with episode dates through October 1 *Data for onset date -based estimates (including imputed) are right -truncated by 14 daysData on 5,136 cases MPX R -effective in California is still trending downwards. Current estimate is <1 through September 16* based on onset dates Using date of lab collection through October 1 rather than date of onset, R - effective is estimated at 0.60 (95% CI: cases by: Los Angeles San Francisco New LHJs reporting cases: No new LHJs at this time Source data last updated 2022 -10-11 12:50:4298Local Health Jurisdictions (continued) 99Case Range Local Health Jurisdiction + (Case Count) 41-50 casesSonoma (45) 31-40 casesSolano (39) 21-30 casesPasadena (28), Stanislaus (26), San Joaquin (25), Ventura (25), Marin (22), Berkeley (21) 11-20 casesMonterey (19), Kern (18), Santa Barbara (16) 01-10 casesPlacer (10), Napa (9), Santa Cruz (9), Yolo (9), Butte (8), Tulare (7), Imperial (6), Shasta (3), El Dorado (2), Kings (2), Humboldt (1), Madera Benito, Sutter, Tuolumne, Yuba * case counts are suppressed for local health jurisdictions with <11 cases and a population < 100,000Cumulative Incidence Rates by Region Source data last updated 2022 -10-11 12:50:42100Monthly Incidence Rates by Region Source data last updated 2022 -10-11 12:50:42101Age and Race/Ethnicity Age Group N Percent* <16 years old 13 0.2 16-24 years old 382 7.2 25-34 years old 1,960 37.1 15.4 55-64 years old 329 6.2 65+ years old 46 0.9 Race/Ethnicity N Percent* Hispanic Or Latino 2,107 44.4 White 1,548 32.6 Black Or African American 612 12.9 Asian 271 5.7 Multiple Or Other Races 166 3.5 Native Hawaiian Or Other Pacific Islander 24 0.5 American Indian Or Alaska Native 19 0.4 Source data last updated 2022 -10-11 12:50:42102Monthly Incidence Rates by Race/Ethnicity Source data last updated 2022 -10-11 12:50:42103Gender and Sexual Orientation Gender N Percent* Male 5,006 96.4 Female 103 2.0 Transgender Female 53 1.0 Transgender Male 16 0.3 Genderqueer/Non -Binary 14 0.3 Sexual Orientation N Percent* Gay/Lesbian/Same -Gender Loving 3,129 80.6 Bisexual 430 11.1 Heterosexual/Straight 318 8.2 Other 6 0.2 Source data last updated 2022 -10-11 12:50:42104Gender and Sexual Orientation* Stratifications Gay -Gender Loving 3,076 82.2 Bisexual 412 11.0 Heterosexual/Straight 251 6.7 Diverse Term 4 0.1 Unknown 1,263 Transgender Male 16 0.3 Gay Or Same -Gender Loving 3 30.0 Bisexual 5 50.0 Heterosexual/Straight Term Female 2.0 7.0 Bisexual 10 14.1 Heterosexual/Straight 56 78.9 Diverse Term 0 0.0 Unknown 32 Transgender Female 53 1.0 Gay/Lesbian/Same -Gender Loving14 53.8 Bisexual 1 3.8 Heterosexual/Straight 10 1 3.8 Unknown 27Other 0.0 Heterosexual/Straight 0 0.0 Diverse Term 0 0.0 Unknown 6 Unknown 86 *As sex assigned at birth was often not reported, counts of cases in cisgender categories could not be reliably distinguished among the \"Male\" and \"Female\" categories of data. **Percentages calculated out of all cases with available data Source data last updated 2022 -10-11 12:50:42105MPX Virus Detections in Wastewater, by Region as of 10.10.2022 106Frequency of detections in wastewater within the last 2 weeks .Testing Volume Update as of 10.09.2022 Source: CDPH Data * Data for week not yet complete ** Labs currently submitting only positive test totals * 107Tests by Lab Submitter, Week Ending 10.09.2022* * Week of October 2 -October 9, 2022 108MPX Clinical Update Jessica Watson, MD, MPH; CDPH 109Provider Advisory: Safe Specimen Collection from MPX Lesions Healthcare Provider Advisory: Safe Specimen Collection From MPX Lesions: DO NOT De-roof Lesions and DO NOT Use Sharps Reduce the risk of MPX virus transmission to health care providers (HCP) during collection of specimens from lesions for MPX diagnosis by adhering to all CDC recommended infection prevention and control measures: oRecommended Personal Protective Equipment oGuidance for safe collection of MPX lesion specimens for diagnostic testing Screen and triage for MPX lesions Don recommended PPE Safe specimen collection -Vigorously swab each lesion, but Do NOT de -roof or aspirate the lesion AND do NOT use sharps. oSpecimen collection print outs 110 CDPH Considerations for Expanded MPX Post -and Pre -Exposure Prophylaxis MPX Provider Survey If you have a patient with MPX who needs Tecovirimat (TPOXX) antiviral treatment, are you able to provide the medication? Yes No Not applicable If you have a patient with MPX who needs Tecovirimat (TPOXX) antiviral treatment, and you are unable toprovide it, do you know where to refer the patient for treatment? Yes No Not applicable111 MPX Vaccine Update Tarek Salih, MPH; CDPH Communicable Disease Control 112Phase 4b.2 Formula for LHJ Demand -based Ordering 113Each Local Health Jurisdiction (LHJ) was provided with a baseline inventory of 20 vials. LHJs with MPX cases were provided additional vaccines above the baseline based on the following formula: 75% based on MPX cases in the past two weeks (9/20/22 - 10/3/22) 25% based on early Syphilis cases among men CDPH Vaccine AllocationExpanded Eligibility for JYNNEOS MPX Vaccine If someone was exposed to MPX <14 days ago, vaccinate them with 2 -doses of JYNNEOS with 28 days between 1st and 2nd dose (PEP and PEP++) If someone is in a high -risk group ,vaccinate them with 2 -doses of JYNNEOS with 28 days between 1st and 2nd dose Pre -Exposure Prophylaxis ( PrEP ). expansion and intradermal injection sites oQuestions and answers relating to pregnant and breastfeeding precautions oPrecautions for those with and without vaccinations Provider/Local Health Jurisdiction Q&A oComing soon116In general, JYNNEOS may be administered without regard to timing of other vaccines. oAdminister each injection in a different injection site. Flu vaccine and JYNNEOS vaccine may be given at the same time. Special considerations for COVID -19 vaccines: oSomeone with recent COVID -19 vaccination: do JYNNEOS if eligible oSomeone with recent JYNNEOS vaccination: some people, particularly adolescent oryoung adult males, might consider delaying COVID -19 vaccination for 4 weeks after JYNNEOS vaccination.JYNNEOS Coadministration Considerations CDC Interim Guidance for Jynneos VaccineMPX Provider Survey 1. Did the switch to intradermal dosing allow your organization to vaccinate more people with your supply? Yes Somewhat No Not Sure 2. Have patients or clients of your agency had any significant adverse reactions after an intradermal dose of JYNNEOS? Yes No Not Sure 3. Do you think intradermal administration of JYNNEOS is leading to any vaccine hesitancy? Yes Somewhat No Not Sure 4. Has intradermal administration of JYNNEOS impacted health equity? Yes Somewhat No Not Sure117 MPX Resources Leslie Amani & CDPH Subject Matter Experts 118CDPH MPX Page: Vaccine Resources Vaccine Q&A for Providers Vaccine Q&A for Public Vaccines Page : oResource Links oAllocation Process Local Health Departments MPX with Resources119 EZIZ MPX Vaccine Resources Includes : Intradermal Clinical guidance Vaccine information Storage and handling Standing orders Coding information Screening checklist EZIZ MPX Resources120121Resources and Support Type of Support Description Access CDPH health care provider MPX clinical guidance including case definitions, diagnosis, laboratory information, healthcare settings, special populations, infection control, case reporting, and vaccine administration/distributionClinical Guidance MPX EZIZ (eziz.org/resources/monkeypox/ ) siteincludes: Intradermal instructions, clinical guidance, vaccine information, storage and handling, standing orders, coding information, screening checklist, and more CDC Information for Healthcare Professionals (www.cdc.gov/poxvirus/monkeypox/clinicians/) site includes case definition, clinical guidance, clinical considerations for pain management, vaccine info, and clinician FAQs Updated 10/11/2022QuestionsEmail MPX questions to MPXinfo@CDPH.ca.gov Or you can submit MPX -related questions to CDPH's online intake portal General information Questions 122 During today's session, please use the Q&A panel to ask your questions so CDPH subject matter experts can respond directly . Resource links will be dropped into \"Chat\" 122Wrap -up Leslie Amani, CDPH 123 Upcoming Opportunities 124 Monday My Turn and myCAvax Office Hours Next session: Monday, October 17 , 12PM Friday Provider Consolidated Webinar Next session: Friday, October 21 , 9AM Note :New session length of 90 -minutes to include COVID -19 "}